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Supplementation with antioxidants and its benefit-risk relationship have been largely discussed in the elderly population. We
evaluated whether antioxidants supplementation improved the biochemical profile associated with oxidative metabolism in elderly
cardiovascular patients. Patients (𝑛 = 112) received daily supplementation with 𝛼-TP 400mg, beta-carotene 40mg, and vitamin
C 1000mg for 2 months (treatment). Plasma concentrations of alpha-tocopherol (𝛼-TP), 𝛽-carotene (𝛽C), ubiquinol-10 (QH-
10), glutathione, and thiobarbituric acid reactive substances (TBARS) were determined before and after treatment. Response to
treatment was dependent on pretreatment 𝛼-TP and 𝛽C levels. Increase in 𝛼-TP and 𝛽C levels was observed only in patients with
basal levels <18𝜇M for 𝛼-TP (𝑃 < 0.01) and <0.30 𝜇M for 𝛽C (𝑃 < 0.02). Ubiquinol-10, glutathione, and TBARS were unaffected
by treatment: QH-10 (+57%, 𝐹
1,110
= 3.611, 𝑃 < 0.06, and N.S.), glutathione (+21%, 𝐹
1,110
= 2.92, 𝑃 < 0.09, and N.S.), and TBARS
(−29%, 𝐹
1,110
= 2.26, 𝑃 < 0.14, and N.S.). Treatment reduced oxidative metabolism: 5.3% versus 14.6% basal value (𝐹
1,110
= 9.21,
𝑃 < 0.0003). Basal TBARS/𝛼-TP ratio was higher in smokers compared to nonsmokers: 0.11 ± 0.02 versus 0.06 ± 0.01 (𝐹
32,80
= 1.63,
𝑃 < 0.04). Response to antioxidant supplementation was dependent on basal plasma levels of 𝛼-TP and 𝛽C. Smoking status was
strongly associated with atherosclerotic cardiovascular disease and high TBARS/𝛼-TP ratio (lipid peroxidation).
1. Introduction
Atherosclerotic cardiovascular diseases are a major cause of
mortality and morbidity in the general population [1].
Numerous studies have focused on the utility of antiox-
idant supplementation in the treatment of cardiovascular
diseases [2]. Yet, whether antioxidant supplementation has
any preventive and/or therapeutic value in cardiovascular
pathology is still a matter of debate for evidence is incon-
clusive [3–9]. Observational studies of vitamins C and E,
the most prevalent natural antioxidant vitamins, suggest that
supplemental use of these vitamins may lower the risk for
coronary events [10]. High doses of antioxidants may pose
risk due to adverse effects [11]. Advertising and marketing
encourage consumption of vitamins supplements regardless
of proper indication and supplements are ready available on-
the-counter for self-medication. The estimated prevalence of
dietary-supplement use among US adults was reported to be
73% not long ago [9]. In some populations, supplements are
consumed to enhance general wellbeing following the advice
of friends and magazines [12].
Oxidative stress results from the imbalance between
oxidativemetabolism and antioxidant activity and is involved
in the pathogenesis of atherosclerotic cardiovascular disease
(ACVD). Reactive oxygen species (ROS) are by-products of
aerobic metabolism that are tightly controlled by antioxi-
dants. Recently the function of ROS in cardiovascular pathol-
ogy has been reviewed [13].
Antioxidants administration has proved to exert pro-
tection against injury in basic research studies [14–17] and
imbalance of the antioxidant-oxidant ratio has been reported
in experimental models of disease [18–20].
The aim of this study was to evaluate whether supple-
mentation with antioxidants effectively modified the bio-
chemical profile associated with oxidative metabolism in
elderly patients undertaking periodical cardiovascular check.
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Vitamin C (ascorbic acid), vitamin E (𝛼-tocopherol), and 𝛽-
carotene are considered important antioxidants in humans
and were tested in this study [21].
2. Materials and Methods
2.1. Design. One-hundred twelve outpatients undertaking
periodical cardiovascular checks (51 men, 61 women, 69
± 5 years, and living in Buenos Aires city) were selected
according to the following criteria. Inclusion criteria are
age (≥65 years), consumers of a varied diet as recorded
in a previous nutritional interview. Exclusion criteria are
heavy alcohol drinkers; patients consuming vitamin supple-
ments; vegetarians, vegans, or followers of any restricted diet;
patients recovering from an illness, surgery, or infectious
process; patients with cerebrovascular events, for example,
brain ischemia or stroke; and patients taking medications
other than what is indicated (see 2nd paragraph below).
The patients were assigned to receive daily supplementa-
tion with 𝛼-TP 400mg, beta-carotene 40mg, and vitamin C
1000mg with dinner for 2 months (end of the study) [22].
This administration schedule was considered appropriate and
safe according to our team of nutritionists. A healthy diet
was designed by one of the authors of this paper (Susana
Vila, medical nutritionist) and the patients signed a written
commitment to follow up the diet through the course of the
study. At the end of the supplementation treatment data were
validated according with a personal nutritional questionnaire
completed by the patients on a daily basis.
Four groups of patients were found among those enrolled
in this study: “Smoker” smoked more than five cigarettes/day
for at least 1 year or after cessation at least 3 months before
the beginning of the study; “atherosclerotic cardiovascu-
lar disease” (ACVD) had one or more of the following:
angina, myocardial infarction, intermittent claudication of
lower extremities, previous history of bypass surgery, or
angioplasty. “Sedentary” regularly exercised for less than
3 hs/week. “Hypertensive” had diastolic/systolic blood pres-
sure over 140/90mmHg when sitting over three measure-
ments at three consecutive visits.The patients went on taking
their respective medication (ACVD: beta-blockers, aspirin,
and statins; hypertensive: angiotensin converting enzyme
inhibitors, angiotensin receptor blockers, or calcium channel
blockers with or without diuretic thiazide) during the study.
The participants signed a written informed consent at the
beginning of the study which was conducted in accordance
with the Declaration of Helsinki (1964).
2.2. Laboratory Analysis. Plasma concentrations of alpha-
tocopherol (𝛼-TP), 𝛽-carotene (𝛽C), ubiquinol-10 (QH-10)
(HPLC-UV-ED), glutathione (enzymatic assay) [23], and
thiobarbituric acid reactive substances (TBARS) (fluorimetry
of lipid oxidation products after plasma incubation in the
appropriate media, excitation 515 nm/555 nm emission) [24]
were determined before (basal) and after antioxidant supple-
mentation (treatment). Percentage of oxidation was calcu-
lated as%TBARS in incubated samples/%TBARS in nonincu-
bated samples.HPLC isocratic reverse phase separationswere
performed using Supelcosil 3 𝜇m LC-8DB column (4.6mm
× 3.3 cm) (Supelco, Bellefonte, USA), LiClO
4
2 × 104 𝜇M in
methanol : H
2
O (99 : 1, v/v) as mobile phase (1mL/min flow
rate). EC detection: a BAS LC4C amperometric detector with
glassy-carbon working electrode (Bioanalytical Systems Inc.,
West Lafayette, IN, USA) is set at +0.6V UV detection: a
Waters 460 Tunable absorbance detector was used (Millipore
Corp., Milford, USA) working at 𝜆 = 275 nm.
Data was submitted to MANOVA followed by multidi-
mensional scaling with cluster analysis or bivariate correla-
tion analyses (Pearson’s product moment correlation coeffi-
cient) in order to evaluate the main effects of treatment, data
distribution, and the degree of association between variables
[25]. Conventionally, the level of statistical significance was
set at 𝑃 < 0.05 (SPSS 15.0 software, SPSS Inc., Chicago, USA).
3. Results and Discussion
The sample of patients comprised smokers (29%), hyper-
tensives (18%), sedentary subjects (63%), and patients with
ACVD (23%).
The following factors were not related to interindividual
variation in basal levels of antioxidants or TBARS: age (𝐹
4,95
=
1.34, 𝑃 < 0.26, and N.S.), diabetes (𝐹
4,95
= 1.41, 𝑃 < 0.23,
and N.S.), ACVD (𝐹
4,95
= 1.45, and 𝑃 < 0.22, N.S.), or
sedentarism (𝐹
4,95
= 0.78, and 𝑃 < 0.54, N.S.).
Smoking status was strongly associated with atheroscle-
rotic cardiovascular disease (ACVD): 42% of smokers had
ACVD compared with 16% of ACVD cases observed in
nonsmokers (correlation coefficient = 0.87, 𝑃 < 0.0001). This
association was not surprising.
Basal TBARS/𝛼-TP ratio (prooxidant/antioxidant imbal-
ance) was higher in smokers compared to nonsmokers: 0.11 ±
0.02 versus 0.06 ± 0.01, respectively (𝐹
32,80
= 1.63, 𝑃 < 0.04)
(Table 1). Alpha-TP, 𝛽C, glutathione, and ubiquinol-10 levels
were dissociated from smoking condition (yet an overall
trend to lower antioxidant levels was observed in smokers).
Plasma levels of either 𝛼-TP or 𝛽C were not affected by
treatment according to average values of the entire sample
of patients. However cluster analysis split the sample into
two categories of patients based on pretreatment 𝛼-TP or 𝛽C
levels and the plasma levels varied accordingly. Increases in
𝛼-TP or 𝛽C levels were observed only in patients with basal
levels below either 18𝜇M for 𝛼-TP (𝑃 < 0.01) or 0.30 𝜇M for
𝛽C (𝑃 < 0.02) (Table 2). The value of 18𝜇M for 𝛼-tocopherol
has been elsewhere considered as the cut point between low
and normal 𝛼-TP plasma concentration ranges [26, 27].
Ubiquinol-10, glutathione, and TBARS levels did not
show significant changes following supplementation irre-
spective of 𝛼-TP and 𝛽C basal levels: QH-10 (57% increase,
𝐹
1,110
= 3.611, 𝑃 < 0.06, and N.S.), glutathione (21% increase,
𝐹
1,110
= 2.92, 𝑃 < 0.09, and N.S.), TBARS (29% decrease,
𝐹
1,110
= 2.26, 𝑃 < 0.14, and N.S.) (Table 2).
Antioxidants supplementation reduced the percentage of
oxidation to 5.26± 0.42% comparedwith 14.60± 2.19% found
at the beginning of the study (𝐹
1,110
= 9.21,𝑃 < 0.0003). Data
analysis revealed that the overall decrease in the percentage
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Table 1: Plasma levels of antioxidants and oxidative stress’ parameters at the beginning of the study.
Smokers (𝑛 = 32) Nonsmokers (𝑛 = 80) Hypertensive (𝑛 = 20) Sedentary (𝑛 = 71) ACVD (𝑛 = 26)
𝛼-TP 19.21 ± 2.73 22.15 ± 2.29 21.33 ± 3.15 21.98 ± 2.34 20.37 ± 2.44
𝛽-Carotene 0.29 ± 0.03 0.34 ± 0.03 0.32 ± 0.05 0.33 ± 0.04 0.27 ± 0.05
Ubiquinol-10 0.22 ± 0.04 0.31 ± 0.05 0.26 ± 0.04 0.26 ± 0.03 0.25 ± 0.07
Glutathione 0.64 ± 0.04 0.73 ± 0.08 0.68 ± 0.06 0.69 ± 0.05 0.67 ± 0.08
TBARS 2.41 ± 0.63 1.31 ± 0.37 1.77 ± 0.36 1.56 ± 0.29 1.97 ± 0.31
TBARS/𝛼-TP 0.13 ± 0.03# 0.06 ± 0.02 0.08 ± 0.02 0.08 ± 0.01 0.10 ± 0.17
Lipid oxidation (%) 18.71 ± 2.49∗ 12.61 ± 2.18 16.62 ± 1.98 15.31 ± 2.27 16.15 ± 2.07
Plasma concentration is expressed in 𝜇M as mean value ± SEM; 𝛼-TP: 𝛼-tocopherol; TBARS: thiobarbituric acid reactive substances.
∗
𝑃 < 0.05, #𝑃 < 0.04 versus nonsmokers.
Table 2: Effect of antioxidant supplementation on biochemical profile related to oxidative metabolism.
Plasma concentration (𝜇M) Sig.
Pretreatment Posttreatment Ratio (post-/pretreatment)
𝛼-TP ≥18 28.56 ± 2.60 1.07 ± 0.09 𝑃 < 0.01
<18 25.76 ± 2.71 1.61 ± 0.11
𝛽C ≥0.30 0.39 ± 0.06 1.05 ± 0.17 𝑃 < 0.02
<0.30 0.49 ± 0.17 2.94 ± 0.36
Ubiquinol-10 0.27 ± 0.02 0.42 ± 0.14 1.57 ± 0.34 NS
Glutathione 0.70 ± 0.02 0.85 ± 0.16 1.21 ± 0.21 NS
TBARS 1.52 ± 0.08 1.07 ± 0.10 0.71 ± 0.09 NS
Lipid oxidation (%) 14.60 ± 2.19 5.26 ± 0.42 0.36 ± 0.08 𝑃 < 0.0003
𝛼-TP: 𝛼-tocopherol; 𝛽C: 𝛽-carotene; TBARS: thiobarbituric acid reactive species. Values are expressed as mean ± SEM.
of lipid oxidation following antioxidant supplementation was
mainly attributable to the change observed in patients with
basal 𝛼-TP levels <18 𝜇M (𝑃 < 0.0003). Only a trend (𝑃 <
0.059, N.S.) was found for the association between the change
in lipid oxidation and 𝛽C baseline levels. This observation
may drive the conclusion that antioxidant supplementation
at the doses administered in the present study, similar
to those routinely found in over-the-counter multivitamin
supplements, may have some benefits irrespective of the
starting 𝛽C plasma levels.
Overall the subjects did not report any beneficial effects
after antioxidants’ supplementation except for subjective
observations such as “feeling more vital” or a feeling of
“general wellbeing”; however, a placebo effect should not be
ruled out.
Association of smoking with high oxidant/antioxidant
ratio has been reported previously [28, 29].
Only a few of severalmeta-analyses of the findings of clin-
ical trials using antioxidant supplementation are mentioned
below [30–34]. Several cohort studies suggested reduced
cardiovascular risk in persons taking vitamin E supplements.
However, randomized clinical trials of vitamin E did not
show any benefit of vitamin E supplementation in terms
of prevention of coronary heart disease and death [30].
Identical rates of cardiovascular death were found for the
placebo and vitamin groups, though a small but significant
increase in CVD was found to be associated with 𝛽-carotene
supplementation in a meta-analysis that included 7 trials
using vitamin E in >81,000 patients and 8 𝛽-carotene trials
with >138,000 patients [31]. A meta-analysis of 19 clinical
trials comprising a total of 135967 participants revealed
that supplementation with high doses (16.5 to 2000 IU/d) of
vitamin E may cause a slight increase in mortality. A further
meta-analysis of the same 19 clinical trials with the inclusion
of 10 additional trials (2495 participants, vitamin E doses 136
to 5000 IU/d) was later performed and yielded contradictory
results. While the former results were confirmed, the results
also indicated that the increased mortality odds ratio was not
related to supplementation with high doses of vitamin E in
some trials [33].
As a part of a European multicentre project, a study (400
healthy volunteers, 25–45 years) reported that supplemen-
tation with alpha-tocopherol and/or carotenoids increased
respective serum levels and that no significant side effects
(except for carotenodermia) or changes in biochemical or
haematological indices had been observed [34].
Oxidative stress has been implicated in pathophysiol-
ogy of aging and age-associated disease and antioxidants
supplementation has become a practice for prevention of
atherosclerosis and cardiovascular disease [35]. Clinical stud-
ies have not demonstrated a benefit of vitamin E in the
primary and secondary prevention of cardiovascular disease.
Vitamin E supplementation was associated with increased
mortality, heart failure, and hemorrhagic stroke [1]. The
American Heart Association does not support the use of
vitamin E supplements to prevent cardiovascular disease and
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recommends the consumption of foods rich in antioxidant
vitamins and minerals [1].
Supplementation is usually decided on the assumption
that endogenous antioxidants’ levels are below the accepted
values sometimes underestimating that adverse effects may
appear. Supplementation adds an extra burden to the liver
and kidneys particularly in elderly patients. A simple labo-
ratory analysis provides information on endogenous antiox-
idants levels and it may additionally help in reaching a
more accurate diagnosis by ruling out (or not) hypothetical7
nutritional deficits.
Two major findings were observed in elderly cardiovas-
cular patients in this study. The increase in plasma levels of
𝛼-TP or 𝛽C was dependent on the respective basal levels.
Smoking status was strongly associated with atherosclerotic
cardiovascular disease and high TBARS/𝛼-TP ratio (lipid
peroxidation).
Higher prevalence of ACVD found in smokers agrees
with the idea of an oxidative pathogenic substrate in ACVD.
No differences were observed in 𝛼-TP, 𝛽C, glutathione,
or ubiquinol-10 plasma levels between smokers and non-
smokers in this study in agreement with previous reports
[36]. Yet, smoking was associated with higher TBARS/𝛼-TP
ratios suggesting an increase in lipid peroxidation relative to
antioxidant activity. To our knowledge, this observation was
not previously reported. Cigarette smoking is widely accepted
to be a major cardiovascular risk factor.
Low plasma levels of antioxidants have been associ-
ated with endothelial dysfunction, the first step towards
atherosclerosis [37, 38] and increased cardiovascular risk. In
the present study we considered the relationship between
ACVD and plasma levels of antioxidants. Our results do
not support the association between ACVD and low serum
concentrations of 𝛼-tocopherol, 𝛽-carotene, glutathione, or
ubiquinol-10. The small number of ACVD patients in this
study (𝑛 = 26) may partly account for this discrepancy.
It is possible that some of these patients had increased
consumption of vegetables and other sources of antioxidants
after they suffered a major event of coronary or peripheral
vascular disease as well. Other authors arrived to similar
results and did not find differences in plasma 𝛼-TP levels
but observed higher 𝛼/𝛾-tocopherol ratio in patients with
coronary heart disease [39].
In this study hypertension, a known risk factor of ACVD,
was not associated with differences in plasma antioxidants or
TBARS concentrations.
4. Conclusions
The effectiveness of antioxidant supplementation to modify
plasma biochemistry as a result of changes in oxidative
metabolism was dependent on basal endogenous antioxi-
dants levels. Present results suggest that awareness of basal
plasma antioxidants levels might be advisable before starting
supplementation with antioxidants in elderly cardiovascular
patients, a population in which special precautions are
recommended. Arguably excess antioxidant levels in tissues
may lead to deleterious consequences [40–42]. However, no
adverse effects were reported during the course of this study.
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